Michael Barbella, Managing Editor05.09.24
NanoVibronix Inc. and Veranex Inc. are partnering to develop the next generation of the former's UroShield and PainShield products. Under the terms of the agreement, Veranex will provide certain research and development services for both products.
“Teaming up with Veranex provides us with access to additional industry expertise and manufacturing know-how to further improve our products and stay ahead of the innovation curve," NanoVibronix CEO Brian Murphy said. "By working with an outside partner with proven methods and techniques to evolve our products, we believe we will be able to offer a next generation of products that not only increases clinician and patient satisfaction but also future-proofs the components and reduces our cost of goods.”
From concept to commercialization, Veranex helps medtech leaders achieve product realization, innovation, clinical trial success, regulatory approval, reimbursement, EU MDR compliance, and preclinical evidence through proven expertise and resources. Its approach ensures that all key functional areas are addressed. The company works in close partnership with clients globally to deliver solutions while ensuring the highest level of quality and compliance.
Headquartered in Elmsford, N.Y., with research and development in Nesher, Israel, NanoVibronix develops medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for various medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals.
“Teaming up with Veranex provides us with access to additional industry expertise and manufacturing know-how to further improve our products and stay ahead of the innovation curve," NanoVibronix CEO Brian Murphy said. "By working with an outside partner with proven methods and techniques to evolve our products, we believe we will be able to offer a next generation of products that not only increases clinician and patient satisfaction but also future-proofs the components and reduces our cost of goods.”
From concept to commercialization, Veranex helps medtech leaders achieve product realization, innovation, clinical trial success, regulatory approval, reimbursement, EU MDR compliance, and preclinical evidence through proven expertise and resources. Its approach ensures that all key functional areas are addressed. The company works in close partnership with clients globally to deliver solutions while ensuring the highest level of quality and compliance.
Headquartered in Elmsford, N.Y., with research and development in Nesher, Israel, NanoVibronix develops medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for various medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals.